---
title: "Lupin share price in focus on approval from USFDA for nasal spray"
date: "2025-02-11 10:05:43"
summary: "Lupin Trade Watchlist Portfolio Message Set Alert livebselivenselive Volume Todays L/H More × Lupin share price will remain in focus on February 11 after the company received United States Food and Drug Administration (USFDA) approval for nasal spray.The USFDA approved company’s Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal..."
categories:
  - "moneycontrol"
lang:
  - "en"
translations:
  - "en"
tags:
  - "moneycontrol"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![Lupin](//stat1.moneycontrol.com/mcnews//images/grey_bg.gif "Lupin")

Lupin
-----

  


  Trade

* [Watchlist](javascript:void(0);)
* [Portfolio](javascript:void(0);)
* [Message](javascript:void(0);)
* [Set Alert](javascript:void(0);)

      live

* bselive
* nselive

    Volume  Todays L/H    ![]()   [More](javascript:void(0))   × 

[Lupin](https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/lupin/L) share price will remain in focus on February 11 after the company received United States Food and Drug Administration (USFDA) approval for nasal spray.

The USFDA approved company’s Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% (21 mcg/spray), to market a generic equivalent of Atrovent Nasal Spray, 0.03%, of Boehringer Ingelheim Pharmaceuticals, Inc.

The product will be manufactured at Lupin’s Pithampur facility in India.

Ipratropium Bromide Nasal Solution id use for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older.

**[Catch all the market action on our live blog](https://www.moneycontrol.com/news/business/markets/stock-market-live-updates-gift-nifty-suggests-a-firm-start-us-asian-markets-gain-liveblog-12936368.html)**

Earlier on February 10, the company with its alliance partner Natco Pharma received an approval from the USFDA for Natco’s ANDA for Bosentan tablets for oral suspension, 32 mg, to market a generic equivalent of Tracleer Tablets for Oral Suspension of Actelion Pharmaceuticals US, Inc.

Natco is the exclusive first-to-file for this product and is eligible for 180 days exclusivity.

A meeting of the board of directors of the company is scheduled to be held on February 11, 2025,  
to consider and approve the unaudited standalone and consolidated financial results of the  
company for the quarter and nine months ended December 31, 2024.

[moneycontrol](https://www.moneycontrol.com/news/business/stocks/lupin-share-price-in-focus-on-approval-from-usfda-for-nasal-spray-12936209.html)
